Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia

• Tipo: Artigo em Revista Científica Internacional
• Data: 2009

Autores

cerveira, n (Autor) Outra; Santos, J (Autor) Outra; Bizarro, S (Autor) Outra; Costa, V (Autor) Outra; Ribeiro, FR (Autor) Outra; Lisboa, S (Autor) Outra; Correia, C (Autor) Outra; Torres, L (Autor) Outra; Vieira, J (Autor) Outra; Snijder, S (Autor) Outra; Mariz, JM (Autor) Outra; Norton, L (Autor) Outra; Mellink, CH (Autor) Outra; Buijs, A (Autor) Outra; Manuel R Teixeira (Autor) ICBAS

Revista

Título: BMC Cancer

Vol. 9

Página Final: 147

ISSN: 1471-2407

Editora: Springer Nature

Indexação

ISI Web of Knowledge - 8 Citações

Scopus - 8 Citações

Outras Informações

ID Authenticus: P-003-JK4

DOI: 10.1186/1471-2407-9-147

Abstract (EN): Background: A relevant role of septins in leukemogenesis has been uncovered by their involvement as fusion partners in MLL-related leukemia. Recently, we have established the MLL-SEPT2 gene fusion as the molecular abnormality subjacent to the translocation t(2;11)(q37;q23) in therapy-related acute myeloid leukemia. In this work we quantified MLL and SEPT2 gene expression in 58 acute myeloid leukemia patients selected to represent the major AML genetic subgroups, as well as in all three cases of MLL-SEPT2-associated myeloid neoplasms so far described in the literature. Methods: Cytogenetics, fluorescence in situ hybridization (FISH) and molecular studies (RT-PCR, qRT-PCR and qMSP) were used to characterize 58 acute myeloid leukemia patients (AML) at diagnosis selected to represent the major AML genetic subgroups: CBFB-MYH11 (n = 13), PML-RARA (n = 12); RUNX1-RUNX1T1 (n = 12), normal karyotype (n = 11), and MLL gene fusions other than MLL-SEPT2 (n = 10). We also studied all three MLL-SEPT2 myeloid neoplasia cases reported in the literature, namely two AML patients and a t-MDS patient. Results: When compared with normal controls, we found a 12.8-fold reduction of wild-type SEPT2 and MLL-SEPT2 combined expression in cases with the MLL-SEPT2 gene fusion (p = 0.007), which is accompanied by a 12.4-fold down-regulation of wild-type MLL and MLL-SEPT2 combined expression (p = 0.028). The down-regulation of SEPT2 in MLL-SEPT2 myeloid neoplasias was statistically significant when compared with all other leukemia genetic subgroups (including those with other MLL gene fusions). In addition, MLL expression was also down-regulated in the group of MLL fusions other than MLL-SEPT2, when compared with the normal control group (p = 0.023) Conclusion: We found a significant down-regulation of both SEPT2 and MLL in MLL-SEPT2 myeloid neoplasias. In addition, we also found that MLL is under-expressed in AML patients with MLL fusions other than MLL-SEPT2.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7